AQST
AQST
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
0
$0
Insider Sales
24
$4.09M
Total Volume
$4.09M
38 transactions
Net Activity
$4.09M
Net selling
Sentiment Rating
Moderate DistributionCEO Conviction Index
Liquidating / Profit Taking
Key Drivers
- •Heavy distribution: sales represent 100% of total transaction value.
- •CEO selling activity detected. Often driven by option expiration or diversification plans.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Barber Daniel
Pres, CEO
$1.88M total
Jung Cassie
COO
$976K total
Boyd Peter E.
Chief People Officer
$337K total
Toth A Ernest Jr
CFO
$243K total
Braender Lori J
GC
$167K total
Quick Actions
AQST has an insider buy conviction of 0%, compared to the Unknown sector buy average of 6%.
Over the last 90 days, corporate insiders at AQST (AQST) engaged in a total of 38 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 24 were sales. The total volume of insider trading reached $4.09M.
The net insider activity for AQST shows a net selling bias of $4.09M. This activity represents a 0% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Barber Daniel (Pres, CEO), who traded 180.7K shares valued at $754K on Mar 10, 2026.
Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus
Aquestive Therapeutics: The Market Is Already Pricing In Anaphylam's Success (NASDAQ:AQST)
AQST Forecast — Price Target — Prediction for 2027
AQST: Aquestive Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Aquestive Therapeutics, Inc. (AQST) Investor Alert: Possible False Statements After 37% Stock Drop
AQST - Aquestive Therapeutics Inc Stock Price and Quote
FAQs About AQST Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for AQST.